Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis

Table 2

Outcomes of direct comparisons in disease activity.

Outcome of disease activity	Comparisons	No. of comparisons	CAS reduction (MD, 95% CI)
7-point CAS	IVGC vs. OGC	1	1.00 [−1.10, 3.10]
	Rtx vs. IVGC	1	1.40 [−0.01, 2.81]
	Rtx vs. placebo	1	0.1 [−1.47, 1.67]
	IVGC + OR vs. OGC + OR	1	0.80 [0.31, 1.29]
	Somastatin vs. placebo	2	0.72 [−0.09, 1.52]
	Somastatin vs. OGC	1	1.00 [0.06, 1.94]
	Teprotumumab vs. placebo	1	1.58 [1.51, 1.65]
10-point CAS	IVGC vs. OGC	2	1.13 [0.40, 1.86]
	IVGC vs. placebo	1	3.49 [2.25, 4.73]
	OR vs. placebo	1	−0.35 [−0.92, 0.22]
	SS vs. placebo	2	0.25 [−0.53, 1.04]
8-point CAS	OGC vs. OIGC	1	−0.25 [−1.12, 0.62]
TES	IVGC vs. IVGC + OR	1	−4.00 [−11.59, 3.59]
	OGC vs. cyclosporin	1	3.60 [−0.45, 7.65]
OI	IVGC vs. OGC	1	1.11 [0.30, 1.92]
	OGC + OR vs. OGC	1	2.51 [1.40, 3.63]

Significant results are in bold.